Horizon Blue Cross and Blue Shield of New Jersey policies, page 7

Search Horizon Blue Cross and Blue Shield of New Jersey's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

834 public policies Substrate tracks for Horizon Blue Cross and Blue Shield of New Jersey, by title.

Horizon Blue Cross and Blue Shield of New Jersey policies
PolicyDetailsCodesSource
Genetic Testing for EpilepsyCommercial—Original policy ↗
Genetic Testing for Facioscapulohumeral Muscular DystrophyCommercial, Medicaid—Original policy ↗
Genetic Testing for Familial Cutaneous Malignant MelanomaCommercial1Original policy ↗
Genetic Testing for Fanconi AnemiaCommercial, Medicaid1Original policy ↗
Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Cytogenetically Normal Acute Myeloid LeukemiaCommercial, Medicaid—Original policy ↗
Genetic Testing for FMR1 Mutations (including Fragile X Syndrome)Commercial2Original policy ↗
Genetic Testing for Helicobacter Pylori TreatmentEffective Aug 1, 2017 · Commercial, Medicaid—Original policy ↗
Genetic Testing for Hereditary Hearing LossCommercial6Original policy ↗
Genetic Testing for Hereditary HemochromatosisCommercial1Original policy ↗
Genetic Testing for Hereditary Pancreatic CancerCommercial, Medicaid—Original policy ↗
Genetic Testing for Hereditary PancreatitisCommercial2Original policy ↗
Genetic Testing for Heterozygous Familial HypercholesterolemiaCommercial—Original policy ↗
Genetic Testing for Idiopathic Dilated CardiomyopathyCommercial1Original policy ↗
Genetic Testing for Inherited ThrombophiliaCommercial, Medicaid2Original policy ↗
Genetic Testing for Lactase InsufficiencyCommercial—Original policy ↗
Genetic Testing for Li-Fraumeni SyndromeCommercial, Medicaid—Original policy ↗
Genetic Testing for Limb-Girdle Muscular DystrophiesCommercial—Original policy ↗
Genetic Testing for Lipoprotein(a) Variant(s) as an Decision Aid for Aspirin TreatmentEffective Aug 1, 2017 · Commercial—Original policy ↗
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer SyndromesCommercial3Original policy ↗
Genetic Testing for Macular DegenerationCommercial—Original policy ↗
Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related DisordersCommercial, Medicaid4Original policy ↗
Genetic Testing for Mitochondrial DisordersCommercial3Original policy ↗
Genetic Testing for NeurofibromatosisCommercial—Original policy ↗
Genetic Testing for Predisposition to Inherited Hypertrophic CardiomyopathyCommercial1Original policy ↗
Genetic Testing for PTEN Hamartoma Tumor SyndromeCommercial—Original policy ↗
Genetic Testing for Rett SyndromeCommercial—Original policy ↗
Genetic Testing for Statin-Induced MyopathyCommercial—Original policy ↗
Genetic Testing for the Diagnosis of Inherited Peripheral NeuropathiesEffective Dec 6, 2018 · Commercial—Original policy ↗
Genotype-Guided Tamoxifen TreatmentCommercial, Medicaid—Original policy ↗
Genotype-Guided Warfarin DosingCommercial, Medicaid—Original policy ↗
Genotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or AneurysmEffective Aug 1, 2017 · Commercial, Medicaid—Original policy ↗
Givosiran (Givlaari)Commercial—Original policy ↗
Golimumab (Simponi Aria)Commercial—Original policy ↗
Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist [Degarelix (Firmagon™)]Commercial—Original policy ↗
Gonadotropin-Releasing Hormone AnalogsCommercial—Original policy ↗
Granulocyte Colony Stimulating Factor (G-CSF - Neupogen, Neulasta, Granix, Zarxio, Fulphila, Nivestym, Udenyca, Ziextenzo, Nyvepria) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF - Leukine)Commercial—Original policy ↗
Greater Occipital Nerve BlockCMM-402 · Commercial, Medicaid5Original policy ↗
H.P. Acthar GelCommercial—Original policy ↗
Handheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins during Breast-Conserving SurgeryCommercial—Original policy ↗
Heart Rate Variability MeasurementCommercial, Medicaid—Original policy ↗
Heart TransplantEffective Jun 10, 2019 · Commercial, Medicaid—Original policy ↗
Heart/Lung TransplantCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Acute Lymphoblastic LeukemiaCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Autoimmune DiseasesCommercial, Medicaid3Original policy ↗
Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and EpendymomaCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Chronic Myeloid LeukemiaCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Epithelial Ovarian CancerCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Hodgkin LymphomaCommercial, Medicaid—Original policy ↗

Back to Horizon Blue Cross and Blue Shield of New Jersey

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.